Topic: ulcerative colitis
Johnson & Johnson's stalwart immunology blockbuster Stelara has been a steady earner for years. But with some areas of its portfolio lagging behind, J&J is hoping that pushing Stelara into new markets can help overcome those stumbles—and keep Stelara generating significant sales for years to come.
It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.
It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.
Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.
Think the success of several megablockbusters such as AbbVie’s Humira means the anti-inflammation market is fully saturated? Think again.
Pfizer totted up a list of accomplishments and milestones in 2018, besides the fact that it managed to eke out growth of about 2% for the year. It reorganized into three business units, for instance, reviving talk of an eventual generics spinoff and setting up its consumer health business for easier disposal.
Pfizer moved rheumatoid arthritis patients to a lower Xeljanz dose after a data monitoring board highlighted safety concerns for the 10-mg arm.
Xeljanz is on a roll. The Pfizer blockbuster scored a big new approval in ulcerative colitis Wednesday, its second FDA win in six months.
With new nods for Pfizer’s Xeljanz and AbbVie’s upadacitinib coming, makers of anti-inflammatory drugs will be feeling the heat from JAK inhibitors.
A new disease awareness campaign from Daiichi Sankyo highlights iron deficits common in patients with Crohn’s disease and ulcerative colitis.